Cardiol Therapeutics (CRDL) investor relations material

Key operational and clinical milestones

• 2023 marked a transformational year, transitioning to late-stage development with the initiation of the pivotal phase III MAVERIC trial for recurrent pericarditis and reporting groundbreaking data from the global ARCHER trial in myocarditis.

• MAVERIC trial surpassed 50% enrollment, with full enrollment expected soon, reflecting strong momentum and engagement from over 20 leading cardiovascular research centers in the U.S.

• ARCHER trial demonstrated the first evidence of structural improvement and reduction in swelling in inflamed hearts, presented at a major cardiology conference and published in a leading journal.

• CRD-38, a next-generation therapy, is advancing toward phase I for heart failure, offering potential for once-monthly dosing and addressing a large unmet need.

• CardiolRx and CRD-38 received broad U.S. patent protection through 2040, enhancing competitive barriers and supporting long-term commercialization strategies.

Clinical trial progress and implications

• MAVERIC phase III trial is designed to demonstrate the impact of CardiolRx on recurrent pericarditis, a condition with significant unmet needs and quality-of-life impacts.

• Enrollment momentum in MAVERIC reflects strong interest from both physicians and patients, with the trial at maximum throughput and nearing completion.

• ARCHER trial addressed myocarditis, a leading cause of sudden cardiac death in young people, with no current standard of care, and showed unprecedented clinical benefits.

• CRD-38 aims to manage chronic inflammation in heart failure, potentially improving outcomes for millions, with a more convenient dosing schedule.

Strategic positioning and future outlook

• CardiolRx and CRD-38 offer oral, non-immune-suppressing therapies, providing improved safety and accessibility compared to expensive biologics.

• U.S. patent and orphan drug designations provide strong market exclusivity and accelerate development timelines.

• The company is positioned to license its drugs to major pharma partners for commercialization, leveraging established commercial infrastructure.

• Analyst coverage includes a reiterated buy rating and $8 price target, reflecting confidence in the company's pipeline and potential for significant value creation.

• With funding secured through at least 2027, the company is well-positioned for continued development and strategic alliances.